Tag «Phase II»

Daprodustat, ダプロデュスタット

It’s only fair to share… Daprodustat, GSK1278863 ダプロデュスタット CAS 960539-70-2 GSK1278863; GSK 1278863; GSK-1278863; Daprodustat C19H27N3O6 Exact Mass: 393.18999 (1,3-dicyclohexyl-2,4,6-trioxohexahydropyrimidine-5-carbonyl)glycine N-[(l,3-dicyclohexyl-6-hydroxy-2,4-dioxo-l,2,3,4- tetrahydro-5-pyrimidinyl)carbonyl]glycine 2-(1,3-dicyclohexyl-2,4,6-triohexahydropyrimidine-5-carboxamide acetic acid Mechanism of Action: HIF-prolyl hydroxylase inhibitor Indication: anemia, diabetic wounds, and reduction of ischemic complications Development Stage: Phase II Developer:GlaxoSmithKline UNII:JVR38ZM64B ダプロデュスタット Daprodustat C19H27N3O6 : 393.43 [960539-70-2] Daprodustat , also known as …

NASTORAZEPIDE

It’s only fair to share…   Nastorazepide (Z-360) CAS: 209219-38-5 Chemical Formula: C29H36N4O5 Molecular Weight: 520.61994 UNII-R22TMY97SG; 209219-38-5; Phase II, treatment of pancreatic cancer. (R)-3-(3-(5-cyclohexyl-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)ureido)benzoic acid Nastorazepide, also known as Z-360, is a selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. Z-360 binds to the gastrin/CCK-2 receptor, thereby preventing receptor activation …

Zydus receives approval from USFDA to initiate Phase II clinical studies of Saroglitazar Magnesium in patients with Primary Biliary Cholangitis (PBC)

It’s only fair to share… Zydus receives approval from USFDA to initiate Phase II clinical studies of Saroglitazar Magnesium in patients with Primary Biliary Cholangitis (PBC) Read more: https://goo.gl/eugRnZ #ZydusAnnouncement Zydus receives approval from USFDA to initiate Phase II clinical studies of Saroglitazar Magnesium in patients with Primary Biliary Cholangitis (PBC) Ahmedabad, India, February 23, …